Explainer

Intuniv for ADHD: How Guanfacine ER Works and What Trials Show

Intuniv (guanfacine ER) was FDA-approved for ADHD ages 6 to 17 in 2009. Its effect size is about 0.7 vs 1.0 for stimulants (AAP, 2019). Trials and side effects.

Mental Health Stats Research Team 7 min read

Key Takeaways

  • Intuniv is extended-release guanfacine, a non-stimulant the FDA approved in 2009 to treat ADHD in children and adolescents aged 6 to 17[1].2009[1]
  • The American Academy of Pediatrics puts the effect size of extended-release guanfacine at about 0.7, compared with about 1.0 for stimulants[2].0.7[2]
  • Sleepiness is the most common side effect: 38% of children and teens on Intuniv in two fixed-dose trials reported somnolence, against 11% on placebo[3].38%[3]
  • Intuniv is approved alone or as an add-on to stimulants; the add-on approval rests on an 8-week trial of 455 children and teens with a suboptimal stimulant response[3].455[3]
  • As of 2021, Japan was the only country to approve it for adults, after a trial of 201 adults found an effect size of 0.52[4][5].0.52[5]
  • Stopping abruptly can cause rebound hypertension, so the label calls for tapering by no more than 1 mg every 3 to 7 days[3].1 mg[3]

What Is Intuniv for ADHD?

Intuniv for ADHD is a once-daily, extended-release form of guanfacine, a non-stimulant medication. The FDA approved it in 2009 to treat symptoms of ADHD in children and adolescents aged 6 to 17[1].

Its current label covers two uses: on its own (monotherapy) and as an add-on to stimulant medication[3]. It comes as 1 mg, 2 mg, 3 mg and 4 mg extended-release tablets[3].

Guanfacine itself is older. It was first approved in the U.S. in 1986 as a blood pressure medicine, and its effects on blood pressure and heart rate account for most of Intuniv's safety warnings[3].

Intuniv is not a central nervous system stimulant or a controlled substance, and its label states it has no known potential for abuse or dependence[3]. How it compares with methylphenidate and amphetamine products as a class is covered in our guide to ADHD meds.

Medication is one part of the recommended approach. For children aged 6 to 11, the AAP guideline recommends FDA-approved medication together with parent training in behavior management and/or behavioral classroom interventions[2]. The evidence on those is in behavior therapy for ADHD, and diagnosis rates by age are on the children and adolescents pages.

Alpha-2A adrenergic agonist

A drug that activates the alpha-2A subtype of adrenergic receptors in the central nervous system. Guanfacine binds this subtype with 15 to 20 times higher affinity than the alpha-2B or alpha-2C subtypes[3]. Stimulating these receptors reduces sympathetic nerve signals to the heart and blood vessels, lowering blood pressure and heart rate; how guanfacine reduces ADHD symptoms is not known[3].

Related Terms

guanfacine extended-release (GXR)
extended-release clonidine
non-stimulant ADHD medication

Source: FDA prescribing information for Intuniv

Does Intuniv Work for ADHD? What the Trials Show

The FDA based Intuniv's approval on seven placebo-controlled trials in children and adolescents aged 6 to 17: five short-term monotherapy trials, one add-on trial with stimulants and one long-term maintenance trial[3]. The short-term monotherapy trials lasted up to 15 weeks[3].

Each trial measured symptoms with the clinician-rated ADHD Rating Scale-IV (ADHD-RS-IV), which covers inattentive and hyperactive-impulsive symptoms[3]. Intuniv reduced scores significantly more than placebo in each one, with placebo-subtracted gaps of 4.5 to 10.0 points (table below)[3].

Benefit rose with dose. Measured by body weight, clinically relevant improvement began at 0.05 to 0.08 mg/kg per day, and doses up to 0.12 mg/kg added further benefit[3].

The American Academy of Pediatrics (AAP) puts the effect size of extended-release guanfacine at about 0.7, the same as atomoxetine and extended-release clonidine and below the roughly 1.0 seen with stimulants[2]. It describes the evidence for these newer non-stimulants as considerably smaller than for stimulants, though adequate for FDA approval[2].

Benefits held in the maintenance trial. Of 526 children and teens who started open-label Intuniv, 315 who responded were randomized to stay on it or switch to placebo for 26 weeks, and significantly fewer treatment failures occurred among those who stayed on Intuniv[3].

Teacher ratings are a weaker point. In a 2018 network meta-analysis of 133 double-blind trials, every included drug beat placebo on clinician ratings in children and adolescents, but only methylphenidate and modafinil beat placebo in the available teacher-rated comparisons[6].

How to read the trial numbers: each figure is a placebo-subtracted difference, the drop in clinician-rated ADHD-RS-IV score on Intuniv minus the drop on placebo. More negative numbers mean larger improvements. The trials ran 5 to 15 weeks, so they describe short-term effects[3].

Intuniv Trials Behind the FDA Approval

TrialAgesDesignPatientsPlacebo-subtracted change
Study 16-17Fixed dose 2-4 mg, 5 weeks345-7.4 to -10.0
Study 26-17Fixed dose 1-4 mg, 6 weeks324-5.4 to -7.9
Study 36-17Add-on to stimulant, 1-4 mg, 8 weeks455-4.5 (morning dose)
Study 46-12Flexible dose 1-4 mg, 8 weeks340-5.3 (morning dose)
Study 513-17Flexible dose 1-7 mg, 15 weeks314-6.0
Study 66-17Flexible dose 1-7 mg, 12-15 weeks337-8.9

Change in clinician-rated ADHD-RS-IV total score with Intuniv minus change with placebo, short-term placebo-controlled trials in children and adolescents[3]

1Ranges in Studies 1 and 2 span the fixed-dose arms; every dose tested was statistically superior to placebo[3].

2Evening dosing in Studies 3 and 4 was also statistically superior to placebo[3].

3Study 7, a 26-week randomized withdrawal trial, is described in the text[3].

Sources

  • •FDA Intuniv prescribing information, 2019

How Intuniv Compares With Stimulants and Strattera

Head-to-head trials are scarce, so comparisons come from network meta-analyses that combine direct and indirect evidence. A 2017 analysis of 36 randomized trials in children and adolescents estimated an 8.68-point placebo-adjusted drop in ADHD-RS-IV score for extended-release guanfacine, against 14.98 points for lisdexamfetamine (Vyvanse) and 6.88 for atomoxetine (Strattera)[7].

That analysis found lisdexamfetamine more effective than Intuniv, and gave Intuniv a high probability of outperforming atomoxetine, although the credible intervals for the two non-stimulants overlapped[7]. It was funded by Shire, the company that also marketed Intuniv[7][3].

An independent 2018 network meta-analysis, weighing efficacy and safety, supported methylphenidate in children and adolescents and amphetamines in adults as preferred first-choice medications for short-term treatment[6].

Intuniv as an add-on to a stimulant

Extended-release guanfacine and extended-release clonidine are the only drugs with enough evidence to have won FDA approval as add-ons to stimulants[2]. The AAP lists add-on therapy as an option when a stimulant is not fully effective or is limited by side effects[2].

In the add-on trial, 455 children and teens with a suboptimal response to a stimulant such as Adderall XR, Vyvanse or Concerta kept their stimulant dose and added Intuniv or placebo for 8 weeks[3]. Symptom scores fell significantly more with Intuniv, whether it was taken in the morning or the evening[3].

ADHD with oppositional defiant disorder

A pooled analysis of four phase 3 trials with 1,084 participants found Intuniv improved core ADHD symptoms in children and teens with and without comorbid oppositional defiant disorder (ODD)[8]. Effect sizes ranged from 0.688 to 0.962 in participants with ODD and from 0.598 to 0.842 in those without it[8].

Estimated Effect vs. Placebo by Drug, Children and Teens

DrugADHD-RS-IV change vs. placeboRelative chance of CGI-I response
Lisdexamfetamine (Vyvanse)-14.982.56
Methylphenidate, extended release-9.332.13
Guanfacine, extended release (Intuniv)-8.681.94
Atomoxetine (Strattera)-6.881.77
Methylphenidate, immediate releaseNo data1.62

Bayesian network meta-analysis of 36 randomized trials of monotherapy in ages 6 to 17, published 2017[7]

1CGI-I response is a clinician rating of overall improvement; the relative chance compares each drug with placebo[7].

2The analysis was funded by Shire, which marketed Intuniv and Vyvanse[7].

Sources

  • •Joseph et al., European Child & Adolescent Psychiatry, 2017

Intuniv Side Effects: Sleepiness, Blood Pressure and Heart Rate

Sleepiness is the side effect most associated with Intuniv. In the two fixed-dose trials, somnolence (including sedation and hypersomnia) was reported by 38% of patients on any dose versus 11% on placebo, rising from 28% at 1 mg to 51% at 4 mg[3].

It tends to be front-loaded. A post hoc analysis of four phase 3 trials found sedative side effects generally peaked in the first week at the target dose and then declined[9]. Symptoms also improved significantly in participants who never reported sedation, and the authors concluded Intuniv's effect is not primarily due to sedation[9].

Blood pressure and heart rate fall with dose. Across the fixed-dose trials, the largest average drops were 5.4 mmHg systolic, 3.4 mmHg diastolic and 5.5 beats per minute[3]. Hypotension was reported in 7% of patients on Intuniv versus 3% on placebo, and fainting (syncope) occurred in 1% of pediatric patients across the clinical program[3].

Side effects drove some dropouts. In the fixed-dose trials, 11% of patients on Intuniv stopped because of adverse reactions, compared with 3% on placebo, and the rate reached 18% at 4 mg[3]. The 2018 network meta-analysis likewise found guanfacine less well tolerated than placebo in children and adolescents (odds ratio 2.64)[6].

Weight change was small. Patients on Intuniv gained 0.5 kg more than those on placebo over comparable periods, and their growth was similar to normative data[3].

The label also warns that Intuniv may worsen sinus node dysfunction and atrioventricular block, and advises avoiding alcohol[3]. The AAP guideline calls for a personal and family cardiac history before non-stimulants are started[2].

Most Common Intuniv Side Effects in Fixed-Dose Trials

Side effectIntuniv, all dosesPlacebo
Somnolence38%11%
Headache23%19%
Fatigue14%3%
Abdominal pain11%9%
Hypotension7%3%
Dizziness6%4%
Lethargy6%3%
Nausea6%2%
Decreased appetite6%4%
Irritability6%4%
Dry mouth4%1%

Share of children and adolescents aged 6 to 17 reporting each adverse reaction, Intuniv (513 patients) vs. placebo (149 patients), Studies 1 and 2[3]

1Somnolence includes somnolence, sedation and hypersomnia; hypotension includes orthostatic hypotension and decreased blood pressure readings[3].

Sources

  • •FDA Intuniv prescribing information, 2019
Children and teens reporting somnolence on Intuniv in fixed-dose trials (11% on placebo)
38%

Somnolence rose with dose, from 28% at 1 mg to 51% at 4 mg, and was the most frequent adverse reaction leading patients to stop treatment in those trials.

"Somnolence and sedation were commonly reported adverse reactions in clinical studies"

U.S. Food and Drug Administration, Intuniv prescribing information(2019) View Source

Intuniv Dosage and How Long It Takes to Work

The label calls for starting at 1 mg once a day and raising the dose by no more than 1 mg per week[3]. The target range is 0.05 to 0.12 mg/kg per day, or 1 to 7 mg in total, set by response and tolerability[3].

Doses above 4 mg a day have not been evaluated in children aged 6 to 12, and doses above 7 mg have not been evaluated in adolescents aged 13 to 17[3]. Doses above 4 mg have not been studied in the add-on setting[3].

The tablet is swallowed whole once a day, morning or evening, at about the same time each day; crushing, chewing or breaking it speeds the release of guanfacine, and high-fat meals raise exposure[3]. Strong and moderate inhibitors of the CYP3A4 enzyme, such as ketoconazole, call for halving the dose[3].

How long does Intuniv take to work?

Because the dose rises in weekly steps, reaching a target dose takes several weeks[3]. In a pooled analysis of four phase 3 trials, the share of responders (a drop of at least 30% in ADHD-RS-IV score) rose from week 1 to week 4 and then held steady to the end of the studies[9].

Intuniv vs. immediate-release guanfacine

Intuniv and immediate-release guanfacine are not interchangeable milligram for milligram[3]. Compared with the same dose of the immediate-release form, Intuniv has a 60% lower peak concentration and 43% lower bioavailability, and it reaches its peak 3 hours later[3]. When switching, the label says to stop the immediate-release form and titrate Intuniv from the starting schedule[3].

Can Adults Take Intuniv for ADHD?

Every trial in the U.S. label enrolled children and adolescents aged 6 to 17, and a 2010 review noted Intuniv was not approved for adults with ADHD[3][1]. As of 2021, Japan was the only country where extended-release guanfacine was approved for adults[4].

The largest adult trial ran in Japan. Among 201 adults randomized to Intuniv (titrated to 4 to 6 mg a day) or placebo, symptom scores fell by 11.55 points versus 7.27 points at week 10, an effect size of 0.52[5].

Clinicians rated 48.1% of the Intuniv group as much or very much improved, against 22.6% on placebo[5]. Side effects led 19.8% of adults on Intuniv to stop, versus 3.0% on placebo, with somnolence, thirst and lower blood pressure among the most common[5].

The trial enrolled only Japanese adults, and six of the seven authors of its follow-up subgroup analysis worked for Shionogi & Co., a Japanese drugmaker[4]. Data on how ADHD affects adults are on the ADHD in adults page.

Stopping Intuniv: Rebound Blood Pressure and Tapering

Stopping Intuniv abruptly can cause clinically significant, persistent rebound hypertension, and hypertensive encephalopathy has been reported in postmarketing cases[3]. The label calls for tapering the total daily dose by no more than 1 mg every 3 to 7 days while monitoring blood pressure and pulse[3].

Even with tapering, blood pressure averaged about 3 mmHg and heart rate 5 beats per minute above original baseline after discontinuation in five pediatric studies[3]. In the maintenance study, the estimated average time for these values to return to baseline was six to twelve months[3].

The label notes that children may be at particular risk because stomach illnesses with vomiting can prevent them from taking doses, and that concurrent stimulant use may increase the rebound[3]. The AAP guideline gives the same advice for guanfacine and clonidine: taper rather than stop suddenly[2]. Broader treatment options are compared in treating ADHD.

Frequently Asked Questions

Sources & References

  1. Cruz MP. Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha2A-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. Pharmacy and Therapeutics. Published 2010. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC2935643/ [Link]
  2. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics (American Academy of Pediatrics). Published 2019. Accessed October 2026. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/Clinical-Practice-Guideline-for-the-Diagnosis [Link]
  3. Shire US Inc. INTUNIV (guanfacine) extended-release tablets, for oral use: full prescribing information. U.S. Food and Drug Administration. Published 2019. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf [Link]
  4. Naya N, Sakai C, Okutsu D, et al. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study. Neuropsychopharmacology Reports. Published 2021. Accessed October 2026. https://onlinelibrary.wiley.com/doi/10.1002/npr2.12152 [Link]
  5. Iwanami A, Saito K, Fujiwara M, et al. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. Published 2020. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/32297719/ [Link]
  6. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. Published 2018. Accessed October 2026. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30269-4/fulltext [Link]
  7. Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. European Child & Adolescent Psychiatry. Published 2017. Accessed October 2026. https://link.springer.com/article/10.1007/s00787-017-0962-6 [Link]
  8. Newcorn JH, Huss M, Connor DF, et al. Efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of Developmental and Behavioral Pediatrics. Published 2020. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/32482970/ [Link]
  9. Huss M, McBurnett K, Cutler AJ, et al. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology. Published 2019. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/30064718/ [Link]

Related Statistics